MBX Biosciences, Inc.
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.55% | -19.16% | -22.41% | -93.56% | -76.25% |
| Total Depreciation and Amortization | 3.45% | -33.33% | -3.17% | 60.42% | 41.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,707.63% | 144.15% | 97.62% | -54.15% | -76.95% |
| Change in Net Operating Assets | 350.08% | -154.53% | -54.53% | 38.25% | 78.05% |
| Cash from Operations | -14.12% | -46.86% | -31.38% | -111.75% | -43.88% |
| Capital Expenditure | -761.96% | -600.00% | -56.42% | 89.01% | -67.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -92.08% | 117.33% | 458.83% | -79.26% | -132.71% |
| Cash from Investing | -93.00% | 116.92% | 429.31% | -79.09% | -132.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 389.74% | 7.77% | 2,552.00% | -97.88% | 926.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -58.10% | 88.44% | -- | -- | -- |
| Cash from Financing | 431.82% | -20.35% | 175.30% | -97.81% | -794.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -77.02% | 52.33% | 143.09% | -496.74% | -108.36% |